Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Phase 3

Terminated

Conditions: Eosinophilic Asthma

Interventions: Drug: Reslizumab

Registration Number: NCT01290887

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Brief Summary: The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by adverse events, physical examination findings, vital sign measurements, and concomitant medication usage throughout the study (every 4 weeks), clinical laboratory test results, and measurement of antidrug antibodies.

Detailed Description: Study patients deemed eligible based on activities from the preceding Teva sponsored double blind study of reslizumab in eosinophilic asthma. Specifically, as per inclusion criterion c, patients must have either completed treatment in a previous Teva-sponsored study or have received at least 2 doses of study drug treatment in a pulmonary function study.

Eligible patients could enroll in this study only after completion of the end of treatment visit in a Teva sponsored, randomized, placebo controlled, double blind study of reslizumab in eosinophilic asthma, which served as the screening/baseline visit for participation in this open label extension study. The use of systemic corticosteroids for asthma in any of the previous Teva sponsored double blind studies of reslizumab did not exclude patients from this study. The previous Teva studies were C38072/3081 (NCT01270464), C38072/3082 (NCT01287039), and C38072/3083 (NCT01285323).

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 1052

Inclusion Criteria

Written informed consent is obtained.
Patient must have completed treatment in a previous Cephalon-sponsored double-blind asthma exacerbation study or received at least 2 doses of study drug treatment in a pulmonary function study.
The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.
other criteria may apply; please contact the investigator for more information.

Exclusion Criteria

The patient has a clinically meaningful comorbidity that would interfere with the study schedule or procedures, or compromise the patient's safety.
The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, or lung cancer).
The patient is a current smoker.
The patient is expected to be poorly compliant with study drug administration, study procedures, or visits.
The patient has any aggravating factors that are inadequately controlled (e.g., gastroesophageal reflux disease [GERD]).
Female patients who are pregnant, or nursing, or, if of childbearing potential and not using a medically accepted, effective method of birth control (eg, spermicide, abstinence, intrauterine device [IUD], or steroidal contraceptive [oral, transdermal, implanted, and injected] in conjunction with a barrier method) are excluded from this study.
The patient has a current infection or disease that may preclude assessment of asthma.
other criteria may apply; please contact the investigator for more information.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Reslizumab 3.0 mg/kg	Reslizumab	Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.

Primary Outcome Measures

Name	Time	Method
Participants With Treatment-Emergent Adverse Events	Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.	An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values	Weeks 4, 8, 24 and 48	Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values on any of the during treatment lab analyses. Significance criteria: * Blood urea nitrogen: \>=10.71 mmol/L * Creatinine: \>=177 μmol/L * Uric acid: M\>=625, F\>=506 μmol/L * Aspartate aminotransferase: \>=3\upper limit of normal (ULN). Normal range is 10-43 U/L Alanine aminotransferase: \>=3\ULN. Normal range is 10-40 U/L GGT = gamma-glutamyl transpeptidase: \>= 3\upper limit of normal. Normal range is 5-49 U/L. Total bilirubin: \>=34.2 μmol/L * White blood cells- low: \<=3.0\10\^9/L White blood cells-high: \>=20\10\^9/L Hemoglobin: M\<=115, F\<=95 g/dL * Hematocrit: M\<0.37, F\<0.32 L/L * Platelets: \>=700\10\^9/L Absolute neutrophil count: \<=1.0\10\^9/L Eosinophils: \>=10 * Urinalysis: ketones, blood, glucose, and total protein: \>=2 unit increase from baseline
Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values	Week 4 to Week 65	Data represents participants with PCS vital sign values during any of the during treatment visits or the follow-up visit. Significance criteria * Sitting heart rate-high: \>100 and increase of \>= 30 beats/min (all ages) * Sitting heart rate-low: \<50 and decrease of \>=30 beats/min * Sitting systolic blood pressure (BP)-high: \>130 and increase of \>=30 mmHg (ages 12-17) * Systolic BP-low: \<90 and decrease of \>=30 mmHg (ages \>=18) * Systolic BP-high: \>160 and increase of \>=30 mmHg (ages \>=18) * Sitting diastolic BP-low: \<55 and decrease of \>=12 mmHg (ages 12-17) * Diastolic BP-high: \>85 and increase of \>=12 mmHg (ages 12-17) * Diastolic BP-low: \<50 and decrease of \>=12 mmHg (ages \>=18) * Diastolic BP-high: \>100 and increase of \>=12 mmHg (ages \>=18) * Respiration rate: \>20 and increase of \>=10 breaths/minute (ages 12-17) * Respiration rate: \>24 and increase of \>=10 breaths/minute (ages \>=18) * Body temperature-low: \<96.5° Fahrenheit (all ages) * Body temp-high: \>100.5° F (all ages)

Secondary Outcome Measures

Name	Time	Method
Forced Vital Capacity (FVC) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint	Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint	The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters. .
Forced Expiratory Flow at 25% to 75% Forced Vital Capacity (FEF 25%-75%) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint	Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint	The FEF 25%-75% is the force expiratory flow at 25% to 75% of the Forced Vital Capacity (FVC), measured in liters/second .
Average Daily Use of Short-Acting Beta-Agonist (SABA)Therapy at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint	Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint	SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit participants were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3. .
Forced Expiratory Volume In 1 Second (FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint	Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint	FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.
Percent Predicted Forced Expiratory Volume In 1 Second (% Predicted FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint	Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint	The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Percent predicted lung function values were transcribed directly from the lung function report to the CRF, without any calculation by Teva.
Asthma Symptom Utility Index (ASUI) Score at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint	Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint	The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control. .
Asthma Control Questionnaire (ACQ) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint	Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint	The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control.
Asthma Quality of Life Questionnaire (AQLQ) Total Score at Weeks 24, 48, 72, 96, End of Study and Endpoint	Weeks 24, 48, 72, 96, End of Study and Endpoint	The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were "patient-specific," which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.
Participants With a Positive Anti-Reslizumab Antibody Status at Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall	Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall	Blood samples were collected for the determination of anti-drug antibody (ADAs) before study drug infusion at baseline and every 24 weeks until end of treatment visit or early withdrawal. Serum samples were analyzed by Teva (Teva Biopharmaceuticals USA, Rockville, Maryland, USA) using a validated homogeneous solution based bridging enzyme linked immune sorbent assay (Mikulsis et al 2011, Qui et al 2010). The analysis of anti-reslizumab antibody in patient serum consists of 3 tiers of assays for screening, confirmation, and titer analysis. If a participant had a treatment-emergent ADA response (ie, ADA positive at any of the postdose time points but negative at the predose time point) or if there was a treatment-boosted ADA response (defined as a greater than 4-fold increase from a positive baseline ADA response (Shankar et at 2014), the participant was classified as overall ADA positive. Predose samples for the reslizumab-experienced participants came from the previous studies.

Trial Locations

Locations (219): Teva Investigational Site 53
🇺🇸
Clearwater, Florida, United States
Teva Investigational Site 19
🇺🇸
Tallahassee, Florida, United States
Teva Investigational Site 46
🇺🇸
Bangor, Maine, United States
Teva Investigational Site 44
🇺🇸
Dallas, Texas, United States
Teva Investigational Site 27
🇺🇸
Miami, Florida, United States
Teva Investigational Site 5
🇺🇸
Miami, Florida, United States
Teva Investigational Site 55
🇺🇸
Miami, Florida, United States
Teva Investigational Site 11
🇺🇸
Fountain Valley, California, United States
Teva Investigational Site 58
🇺🇸
Scottsdale, Arizona, United States
Teva Investigational Site 64
🇺🇸
Boys Town, Nebraska, United States
Teva Investigational Site 12
🇺🇸
Anaheim, California, United States
Teva Investigational Site 41
🇺🇸
Fresno, California, United States
Teva Investigational Site 15
🇺🇸
Walnut Creek, California, United States
Teva Investigational Site 2
🇺🇸
Colorado Springs, Colorado, United States
Teva Investigational Site 4
🇺🇸
Orange, California, United States
Teva Investigational Site 3
🇺🇸
Savannah, Georgia, United States
Teva Investigational Site 6
🇺🇸
Lilburn, Georgia, United States
Teva Investigational Site 460
🇳🇱
Heerlen, Netherlands
Teva Investigational Site 705
🇲🇾
Batu Caves, Malaysia
Teva Investigational Site 207
🇲🇽
Mexico City, Mexico
Teva Investigational Site 422
🇮🇱
Petach Tikva, Israel
Teva Investigational Site 433
🇮🇱
Ramat Gan, Israel
Teva Investigational Site 74
🇺🇸
St. Louis, Missouri, United States
Teva Investigational Site 403
🇭🇺
Sopron, Hungary
Teva Investigational Site 380
🇬🇷
Athens, Greece
Teva Investigational Site 1
🇺🇸
Medford, Oregon, United States
Teva Investigational Site 125
🇦🇷
Rosario, Argentina
Teva Investigational Site 432
🇮🇱
Haifa, Israel
Teva Investigational Site 142
🇧🇷
Santo André, São Paulo, Brazil
Teva Investigational Site 285
🇨🇿
Olomouc, Czech Republic
Teva Investigational Site 300
🇩🇰
Odense, Denmark
Teva Investigational Site 401
🇭🇺
Balassagyarmat, Hungary
Teva Investigational Site 404
🇭🇺
Mosonmagyaróvár, Hungary
Teva Investigational Site 372
🇩🇪
Koblenz, Germany
Teva Investigational Site 701
🇲🇾
Penang, Malaysia
Teva Investigational Site 621
🇺🇦
Dnipropetrovsk, Ukraine
Teva Investigational Site 602
🇸🇪
Göteborg, Sweden
Teva Investigational Site 630
🇺🇦
Ivano-Frankivsk, Ukraine
Teva Investigational Site 622
🇺🇦
Kyiv, Ukraine
Teva Investigational Site 420
🇮🇱
Tel-Aviv, Israel
Teva Investigational Site 587
🇿🇦
Centurion, South Africa
Teva Investigational Site 562
🇸🇰
Topolcany, Slovakia
Teva Investigational Site 624
🇺🇦
Kyiv, Ukraine
Teva Investigational Site 625
🇺🇦
Kyiv, Ukraine
Teva Investigational Site 626
🇺🇦
Vinnytsya, Ukraine
Teva Investigational Site 604
🇸🇪
Göteborg, Sweden
Teva Investigational Site 782
🇹🇭
Bangkok, Thailand
Teva Investigational Site 784
🇹🇭
Nakhon Ratchasima, Thailand
Teva Investigational Site 629
🇺🇦
Donetsk, Ukraine
Teva Investigational Site 580
🇿🇦
Johannesburg, South Africa
Teva Investigational Site 552
🇷🇺
Tomsk, Russian Federation
Teva Investigational Site 603
🇸🇪
Linköping, Sweden
Teva Investigational Site 632
🇺🇦
Zaporizhzhya, Ukraine
Teva Investigational Site 600
🇸🇪
Lund, Sweden
Teva Investigational Site 761
🇨🇳
Taipei, Taiwan
Teva Investigational Site 584
🇿🇦
Cape Town, South Africa
Teva Investigational Site 582
🇿🇦
Durban, South Africa
Teva Investigational Site 589
🇿🇦
Johannesburg, South Africa
Teva Investigational Site 780
🇹🇭
Bangkok, Thailand
Teva Investigational Site 601
🇸🇪
Malmö, Sweden
Teva Investigational Site 586
🇿🇦
Cape Town, South Africa
Teva Investigational Site 585
🇿🇦
Durban, South Africa
Teva Investigational Site 31
🇺🇸
Cincinnati, Ohio, United States
Teva Investigational Site 14
🇺🇸
San Antonio, Texas, United States
Teva Investigational Site 45
🇺🇸
San Antonio, Texas, United States
Teva Investigational Site 50
🇺🇸
Oklahoma City, Oklahoma, United States
Teva Investigational Site 32
🇺🇸
Nashville, Tennessee, United States
Teva Investigational Site 521
🇷🇴
Iasi, Romania
Teva Investigational Site 287
🇨🇿
Brno, Czech Republic
Teva Investigational Site 704
🇲🇾
Taiping, Malaysia
Teva Investigational Site 160
🇨🇱
Rancagua, Chile
Teva Investigational Site 280
🇨🇿
Olomouc, Czech Republic
Teva Investigational Site 742
🇵🇭
Manila, Philippines
Teva Investigational Site 523
🇷🇴
Bucharest, Romania
Teva Investigational Site 522
🇷🇴
Targu Mures, Romania
Teva Investigational Site 563
🇸🇰
Bradejov, Slovakia
Teva Investigational Site 227
🇵🇪
Lima, Peru
Teva Investigational Site 561
🇸🇰
Levice, Slovakia
Teva Investigational Site 161
🇨🇱
Temuco, Chile
Teva Investigational Site 164
🇨🇱
Santiago, Chile
Teva Investigational Site 180
🇨🇴
Floridablanca, Colombia
Teva Investigational Site 286
🇨🇿
Liberec, Czech Republic
Teva Investigational Site 283
🇨🇿
Tabor, Czech Republic
Teva Investigational Site 200
🇲🇽
Hermosillo, Sonora, Mexico
Teva Investigational Site 225
🇵🇪
Lima, Peru
Teva Investigational Site 226
🇵🇪
Lima, Peru
Teva Investigational Site 743
🇵🇭
Quezon City, Philippines
Teva Investigational Site 520
🇷🇴
Cluj-Napoca, Romania
Teva Investigational Site 162
🇨🇱
Valdivia, Chile
Teva Investigational Site 181
🇨🇴
Bogotá, Colombia
Teva Investigational Site 281
🇨🇿
Olomouc, Czech Republic
Teva Investigational Site 740
🇵🇭
Quezon City, Philippines
Teva Investigational Site 741
🇵🇭
Quezon City, Philippines
Teva Investigational Site 205
🇲🇽
Ciudad De México, Mexico
Teva Investigational Site 209
🇲🇽
Monterrey, Mexico
Teva Investigational Site 221
🇵🇪
Lima, Peru
Teva Investigational Site 229
🇵🇪
Lima, Peru
Teva Investigational Site 745
🇵🇭
Quezon City, Philippines
Teva Investigational Site 524
🇷🇴
Bucharest, Romania
Teva Investigational Site 560
🇸🇰
Spisska Nova Ves, Slovakia
Teva Investigational Site 763
🇨🇳
Taoyuan, Taiwan
Teva Investigational Site 47
🇺🇸
Denver, Colorado, United States
Teva Investigational Site 8
🇺🇸
Omaha, Nebraska, United States
Teva Investigational Site 554
🇷🇺
Moscow, Russian Federation
Teva Investigational Site 558
🇷🇺
Moscow, Russian Federation
Teva Investigational Site 541
🇷🇺
St. Petersburg, Russian Federation
Teva Investigational Site 559
🇷🇺
Moscow, Russian Federation
Teva Investigational Site 63
🇺🇸
Boerne, Texas, United States
Teva Investigational Site 16
🇺🇸
Fort Worth, Texas, United States
Teva Investigational Site 546
🇷🇺
Yaroslavl, Russian Federation
Teva Investigational Site 428
🇮🇱
Jerusalem, Israel
Teva Investigational Site 59
🇺🇸
Long Beach, California, United States
Teva Investigational Site 43
🇺🇸
Los Angeles, California, United States
Teva Investigational Site 28
🇺🇸
Waterbury, Connecticut, United States
Teva Investigational Site 34
🇺🇸
Colorado Springs, Colorado, United States
Teva Investigational Site 24
🇺🇸
Largo, Florida, United States
Teva Investigational Site 17
🇺🇸
Trinity, Florida, United States
Teva Investigational Site 18
🇺🇸
Valrico, Florida, United States
Teva Investigational Site 25
🇺🇸
Lawrenceville, Georgia, United States
Teva Investigational Site 49
🇺🇸
Lexington, Kentucky, United States
Teva Investigational Site 40
🇺🇸
St. Louis, Missouri, United States
Teva Investigational Site 20
🇺🇸
Cincinnati, Ohio, United States
Teva Investigational Site 26
🇺🇸
Summit, New Jersey, United States
Teva Investigational Site 66
🇺🇸
Altoona, Pennsylvania, United States
Teva Investigational Site 73
🇺🇸
Lincoln, Rhode Island, United States
Teva Investigational Site 9
🇺🇸
Providence, Rhode Island, United States
Teva Investigational Site 69
🇺🇸
El Paso, Texas, United States
Teva Investigational Site 126
🇦🇷
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 33
🇺🇸
Madison, Wisconsin, United States
Teva Investigational Site 121
🇦🇷
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 127
🇦🇷
Ciudad Autonoma de Buenos Aire, Argentina
Teva Investigational Site 128
🇦🇷
Quilmes-Buenos Aires, Argentina
Teva Investigational Site 123
🇦🇷
Rosario-Santa Fe, Argentina
Teva Investigational Site 120
🇦🇷
San Miguel de Tucuman - Tucuma, Argentina
Teva Investigational Site 642
🇦🇺
Frankston, Australia
Teva Investigational Site 641
🇦🇺
East Bentleigh, Australia
Teva Investigational Site 122
🇦🇷
San Miguel de Tucuman - Tucuma, Argentina
Teva Investigational Site 264
🇧🇪
Bruxelles, Belgium
Teva Investigational Site 645
🇦🇺
Liverpool, Australia
Teva Investigational Site 261
🇧🇪
Bruxelles, Belgium
Teva Investigational Site 260
🇧🇪
Gent, Belgium
Teva Investigational Site 643
🇦🇺
Nedlands, Australia
Teva Investigational Site 262
🇧🇪
Jambes, Belgium
Teva Investigational Site 263
🇧🇪
Liège, Belgium
Teva Investigational Site 146
🇧🇷
Belo Horizonte, Brazil
Teva Investigational Site 103
🇨🇦
Calgary, Canada
Teva Investigational Site 150
🇧🇷
Florianopolis, Brazil
Teva Investigational Site 147
🇧🇷
Porto Alegre - RS, Brazil
Teva Investigational Site 143
🇧🇷
Porto Alegre, RS, Brazil
Teva Investigational Site 140
🇧🇷
Porto Alegre, Brazil
Teva Investigational Site 144
🇧🇷
Porto Alegre, Brazil
Teva Investigational Site 101
🇨🇦
Montreal, Canada
Teva Investigational Site 104
🇨🇦
Newmarket, Canada
Teva Investigational Site 105
🇨🇦
Windsor, Canada
Teva Investigational Site 166
🇨🇱
Valparaiso, Chile
Teva Investigational Site 185
🇨🇴
Bogota, Colombia
Teva Investigational Site 182
🇨🇴
Cali, Colombia
Teva Investigational Site 284
🇨🇿
Breclav, Czech Republic
Teva Investigational Site 341
🇫🇷
Montpellier, France
Teva Investigational Site 342
🇫🇷
Marseille, France
Teva Investigational Site 361
🇩🇪
Berlin, Germany
Teva Investigational Site 366
🇩🇪
Berlin, Germany
Teva Investigational Site 371
🇩🇪
Bochum, Germany
Teva Investigational Site 370
🇩🇪
Hamburg, Germany
Teva Investigational Site 369
🇩🇪
Frankfurt, Germany
Teva Investigational Site 367
🇩🇪
Leipzig, Germany
Teva Investigational Site 363
🇩🇪
Mainz, Germany
Teva Investigational Site 400
🇭🇺
Miskolc, Hungary
Teva Investigational Site 407
🇭🇺
Szazhalombatta, Hungary
Teva Investigational Site 402
🇭🇺
Tatabánya, Hungary
Teva Investigational Site 405
🇭🇺
Törökbálint, Hungary
Teva Investigational Site 423
🇮🇱
Ashkelon, Israel
Teva Investigational Site 425
🇮🇱
Jerusalem, Israel
Teva Investigational Site 426
🇮🇱
Kfar Saba, Israel
Teva Investigational Site 421
🇮🇱
Rehovot, Israel
Teva Investigational Site 680
🇰🇷
Seoul, Korea, Republic of
Teva Investigational Site 682
🇰🇷
Gwangju, Korea, Republic of
Teva Investigational Site 681
🇰🇷
Seoul, Korea, Republic of
Teva Investigational Site 686
🇰🇷
Seoul, Korea, Republic of
Teva Investigational Site 683
🇰🇷
Seoul, Korea, Republic of
Teva Investigational Site 685
🇰🇷
Suwon, Korea, Republic of
Teva Investigational Site 700
🇲🇾
Kuala Lumpur, Malaysia
Teva Investigational Site 702
🇲🇾
Kuala Lumpur, Malaysia
Teva Investigational Site 203
🇲🇽
Distrito Federal, Mexico
Teva Investigational Site 204
🇲🇽
Guadalajara, JAL, Mexico
Teva Investigational Site 202
🇲🇽
Tijuana, B.C., Mexico
Teva Investigational Site 724
🇳🇿
Dunedin, New Zealand
Teva Investigational Site 727
🇳🇿
Hamilton, New Zealand
Teva Investigational Site 723
🇳🇿
Auckland, New Zealand
Teva Investigational Site 720
🇳🇿
Tauranga, New Zealand
Teva Investigational Site 721
🇳🇿
Wellington, New Zealand
Teva Investigational Site 223
🇵🇪
Cercado de Lima, Lima, Peru
Teva Investigational Site 220
🇵🇪
Lima, Peru
Teva Investigational Site 222
🇵🇪
Lima, Peru
Teva Investigational Site 509
🇵🇱
Bydgoszcz, Poland
Teva Investigational Site 512
🇵🇱
Lodz, Poland
Teva Investigational Site 511
🇵🇱
Poznan, Poland
Teva Investigational Site 504
🇵🇱
Tarnow, Poland
Teva Investigational Site 545
🇷🇺
Barnaul, Russian Federation
Teva Investigational Site 549
🇷🇺
Kemerovo, Russian Federation
Teva Investigational Site 543
🇷🇺
Moscow, Russian Federation
Teva Investigational Site 544
🇷🇺
Moscow, Russian Federation
Teva Investigational Site 555
🇷🇺
Novosibirsk, Russian Federation
Teva Investigational Site 540
🇷🇺
St.Petersburg, Russian Federation
Teva Investigational Site 542
🇷🇺
St. Petersburg, Russian Federation
Teva Investigational Site 557
🇷🇺
Novosibirsk, Russian Federation
Teva Investigational Site 583
🇿🇦
Pretoria, South Africa
Teva Investigational Site 588
🇿🇦
Pretoria, South Africa
Teva Investigational Site 623
🇺🇦
Kyiv, Ukraine
Teva Investigational Site 620
🇺🇦
Kharkiv, Ukraine
Teva Investigational Site 52
🇺🇸
Orlando, Florida, United States
Teva Investigational Site 30
🇺🇸
Winston-Salem, North Carolina, United States
Teva Investigational Site 21
🇺🇸
Charleston, South Carolina, United States
Teva Investigational Site 507
🇵🇱
Bialystok, Poland
Teva Investigational Site 513
🇵🇱
Gdansk, Poland
Teva Investigational Site 500
🇵🇱
Ostrow Wielkopolski, Poland
Teva Investigational Site 505
🇵🇱
Lublin, Poland
Teva Investigational Site 633
🇺🇦
Kharkiv, Ukraine
Teva Investigational Site 631
🇺🇦
Zaporizhzhia, Ukraine